Stage III Ovarian Cancer: Dianne's Patient Story

Patient Info: Dianne Simpson, female, 70+ | Stage III

Dianne completed treatment in April 2017 after chemotherapy, hysterectomy and a pembrolizumab clinical trial and was looking ahead to survivorship.

MD AndersonRead more →

How I Told My Young Children I Had Cancer

Patient Info: Anonymized, Female

Completed chemotherapy in August 2014 and her final surgery in November 2014.

Dana-FarberRead more →

ERBB2-Mutated Stage III Lung Cancer With Liver Recurrence and Multiple Lines of Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion

Metastatic Site: liver

After 6 months of disease control on vinorelbine plus trastuzumab, the cancer progressed in all sites and she chose hospice care.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Adenocarcinoma With Brain Metastases and Multiple Targeted Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ERBB2 exon 20 insertion, exact sequence not specified. ERBB2 copy-number gain was identified during progression on afatinib.

Metastatic Site: brain, adrenal gland, liver

The final documented afatinib plus bevacizumab rechallenge produced a mixed response followed by liver progression after 3 months.

PubMed CentralRead more →

Stage IV Ovarian Cancer: Diane's Patient Story

Patient Info: Diane Sarver, female | Stage IV

After about 7 weeks on the clinical trial, Diane's test results had normalized; she was entering her third year on treatment and planned to continue while it remained effective and tolerable.

MD AndersonRead more →

Lung Cancer Immunotherapy Caused New Type 1 Diabetes

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No ALK, ROS1, KRAS or EGFR alteration was detected; CK7-positive; TTF-1-negative; PAX-negative; CK20-negative

Metastatic Site: Pleura

After 4 combination-treatment cycles, the right-lung nodules had decreased markedly and nearly resolved. He continued maintenance pembrolizumab every 3 weeks and remained on insulin with stable glucose control.

PubMed CentralRead more →

Metastatic lung cancer controlled on AZD9291 clinical trial with tracheal narrowing under review

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: Metastasis mentioned; site not specified in this entry

On 20 November 2016, the patient’s tumor and metastasis appeared controlled on AZD9291 and the disease was not considered progressive, though tracheal narrowing required closer review and earlier follow-up.

Metastatic lung cancer on AZD9291 with a left iliac bone lesion

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: Bone: left iliac bone

On 18 September 2016, the patient was living with lung cancer on AZD9291 after MRI confirmed a solitary left iliac bone lesion suspicious for metastasis, with radiotherapy deferred and the next CT planned for November.

Lung cancer on AZD9291 with tumor shrinkage and new suspected iliac bone metastasis

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: Bone: left sacroiliac/iliac region

On 28 August 2016, AZD9291 had reduced the lung mass and stabilized nodes, but CT also showed a new suspected left iliac/sacroiliac bone metastasis requiring MRI workup.

EGFR-mutated lung cancer on AZD9291 clinical trial with improved symptoms

Patient Info: Anonymized, Male

Biomarkers: EGFR mutation

On 20 July 2016, the patient was on AZD9291 through a clinical trial, toxicity checks were reassuring, symptoms felt improved, and the next CT was planned for late August.

Lung cancer progression with T790M-positive tissue result and AZD9291 trial start

Patient Info: Anonymized, Male | Stage Metastatic/Advanced

Biomarkers: resistance detected in tissue biopsy

On 5 June 2016, CT showed lung tumor progression after afatinib, but a tissue T790M result allowed entry into an AZD9291 clinical trial and treatment had just started.

Stage II Invasive Ductal Carcinoma: Sarah's Patient Story

Patient Info: Sarah Cawley, Female, Under 40 | Stage II

As of August 2015, Sarah was still receiving treatment for Stage II invasive ductal carcinoma after modified radical mastectomy, 6 chemotherapy cycles, 25 radiation treatments and clinical trial participation.

Cleveland ClinicRead more →

Stage III BRCA1 Ovarian Cancer: Meredith's Survivor Story

Patient Info: Meredith Ippolito, female | Stage III

Biomarkers: BRCA1 mutation

Meredith was told she was cancer-free in April 2009 and continued follow-up visits every 6 months.

MD AndersonRead more →

Stage IV Ovarian Cancer: Bre's Patient Story

Patient Info: Bre Tipps, female, Under 40 | Stage IV

A recent CT scan showed the remaining tumors calcifying and dying during hormonal therapy, although the patient expected to need ongoing ovarian cancer treatment.

MD AndersonRead more →

Stage III Ovarian Cancer in a BRCA1 Carrier Treated With Long-Term Maintenance Therapy

Patient Info: Anonymized, 50s | Stage III

Biomarkers: BRCA1 mutation

After long-term maintenance therapy, she had no evidence of ovarian cancer at the latest follow-up.

PubMed CentralRead more →

Recurrent Stage III Ovarian Cancer in a BRCA2 Carrier Treated Over Many Years

Patient Info: Anonymized, 40s | Stage III

Biomarkers: BRCA2 mutation

She later developed a separate aggressive oral squamous cell carcinoma and died in 2011 from acute airway obstruction during progression of that cancer.

PubMed CentralRead more →

Recurrent Stage III Ovarian Cancer in a BRCA1 Carrier Treated With Multiple Therapies

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: BRCA1 mutation

By late 2011, hilar nodal disease was slowly progressing and bevacizumab was started for the recurrent ovarian cancer.

PubMed CentralRead more →

Recurrent Stage III Ovarian Cancer Complicated by Severe Kidney Injury

Patient Info: Anonymized, female, 70+ | Stage III

After further intra-abdominal cancer progression and severe kidney injury, she developed seizures, encephalopathy, and limb ischemia and died 1 week after hospitalization in May 2011.

PubMed CentralRead more →